Sergey Brin’s family office, Bayshore Global Management, has reportedly taken over a neuroscience-focused venture fund, bringing its activities in-house as part of a broader push to centralize investment control, according to Bloomberg. The fund, Nexus NeuroTech Ventures, which oversaw more than $200 million in assets, is being shut down as a standalone entity and folded into Bayshore.
Nexus specialized in brain health and neuroscience investments, supporting companies working on treatments and technologies for neurological conditions. Its portfolio is now being absorbed into Bayshore, effectively consolidating Brin’s bets in the space under one roof.
The move reflects a wider shift among ultra-wealthy investors and family offices toward bringing external investment strategies in-house. By internalizing the fund, Bayshore can exercise more direct control over capital deployment, portfolio decisions, and long-term direction—especially in complex areas like neurotechnology.
Brin has been a long-time supporter of brain health research and neurological initiatives, and the integration signals an ongoing commitment to the sector. It also comes amid growing investor interest in neuroscience, fueled by advances in AI and biotechnology.
More broadly, family offices are becoming increasingly influential in venture and growth investing, often benefiting from longer investment horizons and fewer constraints than traditional VC firms. The absorption of Nexus into Bayshore underscores how these platforms are evolving into fully integrated investment operations capable of sourcing and managing sophisticated portfolios independently.
Although Nexus will cease to exist as a separate fund, its investments will continue under Bayshore’s management, preserving exposure to the neurotechnology space while simplifying Brin’s overall investment structure.
